Survival After Combined Modality Therapy for Pancreatic Cancer
- 1 April 1993
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Journal of Clinical Gastroenterology
- Vol. 16 (3) , 199-203
- https://doi.org/10.1097/00004836-199304000-00006
Abstract
Twenty consecutive patients with unresectable, locally advanced pancreatic cancer were treated with split courses of radiotherapy (RT) and simultaneous multidrug chemotherapy consisting of 5 fluorouracil, continuous infusion, streptozotocin, and cisplatin. A separate, retrospective study identified a group of 28 contemporary patients with less advanced pancreatic cancers, all of which were successfully resected. The survival rate of the two groups were similar over the first 2 years, although it initially favored the unresectable group. This pattern of survival among patients treated with combined modality therapy provides a basis for new studies. At the two clinical extremes, these include treatment of unresectable tumors previously considered ineligible for this treatment and initial treatment before resection of stage I tumors.Keywords
This publication has 0 references indexed in Scilit: